Amgen Announces Its Phase 3 OASIZ 301 Trial Of Dazodalibep To Treat Sjogren's Disease Meets Primary Endpoint, Shows Improvement In Systemic Disease Activity At Week 48

Amgen (NASDAQ: AMGN) announced positive topline results from its Phase 3 OASIZ 301 trial of dazodalibep for treating Sjögren's disease, achieving its primary endpoint with significant improvement in systemic disease activity at Week 48. The study showed early improvements in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) as soon as Week 4, which were maintained throughout the trial duration.